U.S. Cardiovascular KOL Intelligence Report · Lipid Disorder Management

What 25 U.S. Cardiovascular KOLs Reveal About the Future of Lipid Disorder Management

Expert perspectives on lipid-lowering therapies, treatment intensification, cardiovascular risk assessment, biomarkers, access barriers, AI-supported care and the future direction of dyslipidemia management.

25 KOLs
U.S. Market
8 Survey Questions
KOL Perception Study
Lipid
Intelligence
Non-Statin Therapies PCSK9 & targeted care
Biomarkers Lp(a) & ApoB
AI & Digital Risk & treatment support
Access Cost & authorization
Executive Snapshot

Lipid management is entering a new phase of therapeutic and diagnostic innovation.

Cardiovascular disease remains the leading cause of death in the United States, and lipid disorder management sits at the center of prevention strategy. This survey of 25 U.S. cardiovascular and lipidology Key Opinion Leaders reveals a field in transition: therapies are expanding, biomarkers are reshaping risk stratification, and digital health tools are moving from pilot programs into everyday practice.

According to the findings, 92% of KOLs describe the need for continued innovation in dyslipidemia management as high or very high — a signal that, despite decades of statin dominance, the market is far from saturated.

This KOL perception study offers pharma, biotech, and MedTech stakeholders a data-backed view into where lipid-lowering therapies, cardiovascular risk assessment, and treatment access are heading next.

92%
Innovation remains essential

Describe the need for continued innovation in dyslipidemia management as high or very high.

84%
Current options leave gaps

Characterize existing treatment options as only partially adequate.

88%
Biomarkers are central

Rate Lp(a), ApoB, genetic testing and other biomarkers extremely important for cardiovascular risk assessment.

84%
AI adoption is likely

Believe digital health technologies and AI-supported tools are likely or very likely to become part of lipid management.

The Bigger Picture

The Lipid Management Innovation Shift

The emerging model connects non-statin treatment innovation with treatment intensification, biomarker-driven risk assessment, digital health, AI and improved access.

01

Non-Statin & Targeted Therapies

Expand treatment options beyond statins to address residual cardiovascular risk.

02

Oral PCSK9 Inhibition

Move toward oral approaches that can reduce treatment burden associated with injectable therapies.

03

Combination & Intensification

Layer agents with complementary mechanisms to reach aggressive LDL-C targets faster.

04

Biomarker-Driven Risk

Use Lp(a), ApoB and genetic testing to support a fuller cardiovascular risk profile.

05

AI & Digital Health

Support risk stratification, patient identification and treatment intensification decisions.

06

Access & Implementation

Translate therapeutic and diagnostic innovation into accessible real-world care.

Expert Perspective

What Are Cardiovascular KOLs Signaling?

Across the eight survey questions, the strongest signals point to continued unmet need, growing importance of biomarkers, access challenges and confidence in digital health and AI-supported lipid management.

01 · UNMET NEED
92%

Innovation remains necessary

Very High / High need for continued innovation in lipid disorder management.

02 · PRECISION RISK
88%

Biomarkers are highly important

Rate Lp(a), ApoB, genetic testing and other biomarkers extremely important for cardiovascular risk assessment.

03 · FUTURE OUTLOOK
94%

Experts remain optimistic

Optimistic / Very optimistic about the future of lipid disorder management over the next decade.

Survey Findings

8 Questions. 25 Expert Perspectives.

25 Key Opinion Leaders
Q1
Need for continued innovation
92%
Q2
Adequacy of current treatment options
84%
Q3
Most important recent advancement
72%
Q4
Importance of Lp(a), ApoB, genetic testing & biomarkers
88%
Q5
Importance of earlier risk identification & treatment
88%
Q6
Greatest implementation barrier
68%
Q7
Digital health technologies & AI adoption
84%
Q8
Future outlook
94%
Detailed Response Distribution

What the Survey Data Shows

Question 01

How significant is the need for continued innovation in lipid disorder management?

92%
Very High / High Need
Very High
60%
High
32%
Moderate
4%
Low
4%
What this means

Very High / High = 92%, showing that continued innovation remains a clear priority among surveyed cardiovascular and lipidology KOLs.

Question 02

Are current treatment options adequately addressing the needs of patients with lipid disorders?

84%
Partially Adequate
Fully adequate
8%
Partially adequate
84%
Inadequate
8%
What this means

Only 8% call current options fully adequate, while 84% describe them as partially adequate and 8% as inadequate. The findings point to residual cardiovascular risk and continued need for innovation.

Question 03

Which development has been the most important recent advancement in lipid management?

72%
Expanded Non-Statin & Targeted Therapies
Expanded non-statin and targeted lipid-lowering therapies, including oral PCSK9 inhibition
72%
Treatment intensification and combination therapy
12%
Long-acting lipid-lowering approaches
8%
Biomarker-driven risk assessment and personalized management
8%
What this means

Expanded non-statin and targeted lipid-lowering therapies, including oral PCSK9 inhibition, are identified as the leading recent advancement, followed by treatment intensification, long-acting approaches and biomarker-driven management.

Question 04

How important are Lp(a), ApoB, genetic testing and other biomarkers for cardiovascular risk assessment?

88%
Extremely Important
Extremely important
88%
Moderately important
12%
What this means

Lp(a), ApoB, genetic testing and other biomarkers have moved from research interest to clinical priority, with 88% of KOLs rating them extremely important for cardiovascular risk assessment.

Question 05

How important is earlier identification and treatment of elevated cardiovascular risk?

88%
Extremely / Very Important
Extremely important
56%
Very important
32%
Moderately important
8%
Slightly important
4%
What this means

Extremely / Very important = 88%, highlighting the priority KOLs place on earlier identification and treatment of elevated cardiovascular risk.

Question 06

What is the greatest barrier to broader implementation of advanced lipid management?

68%
Cost, Insurance & Prior Authorization
High treatment costs, insurance restrictions & prior authorization requirements
68%
Treatment adherence and persistence
12%
Limited access to lipid/cardiovascular specialists
12%
Limited use of advanced biomarkers/genetic testing
8%
What this means

Cost, insurance restrictions and prior authorization requirements are the greatest barrier cited by KOLs, ahead of adherence, specialist access and limited use of advanced biomarker or genetic testing.

Question 07

How likely are digital health technologies and AI-supported tools to become part of lipid management?

84%
Likely / Very Likely
Very likely
48%
Likely
36%
Neutral
12%
Unlikely
4%
What this means

Likely / Very likely = 84%, indicating strong expectations that digital health and AI-supported tools will become part of routine lipid management.

Question 08

How optimistic are you about the future of lipid disorder management over the next decade?

94%
Optimistic / Very Optimistic
Very optimistic
48%
Optimistic
46%
Neutral
4%
Pessimistic
2%
What this means

Optimistic / Very optimistic = 94%, reflecting a strongly positive expert outlook for lipid disorder management over the next decade.

Innovation Spotlight

Oral PCSK9 Inhibition Emerges as the Standout Development

When asked to identify the single most important recent advancement, 72% of KOLs pointed to expanded non-statin and targeted lipid-lowering therapies — with oral PCSK9 inhibition specifically named as the standout development.

Other advancements flagged by KOLs include treatment intensification and combination therapy, long-acting lipid-lowering approaches, and biomarker-driven, personalized risk assessment.

72%

Non-Statin & Targeted Therapies

Expanded non-statin and targeted lipid-lowering therapies, including oral PCSK9 inhibition.

12%

Combination Therapy

Treatment intensification and combination therapy to hit aggressive LDL-C targets faster.

8% + 8%

Long-Acting & Personalized Approaches

Long-acting lipid-lowering approaches and biomarker-driven, personalized management were also identified.

The Access Gap

The Real Barrier Isn't Science — It's Access

Despite therapeutic advances, broader implementation is constrained by treatment cost, insurance restrictions and prior authorization requirements.

Therapeutic Innovation

What is changing

  • Expanded non-statin therapies
  • Oral PCSK9 inhibition
  • Treatment intensification and combination therapy
  • Long-acting lipid-lowering approaches
  • Biomarker-driven personalized management
Real-World Barriers

What can slow adoption

  • Treatment cost
  • Insurance restrictions
  • Prior authorization requirements
  • Treatment adherence and persistence
  • Limited access to lipid/cardiovascular specialists
68%
identified treatment cost, insurance restrictions and prior authorization requirements as the greatest barrier.
AI & Digital Health

AI in Lipid Management: From Pilot to Practice

Digital health and AI-supported tools are no longer a speculative frontier in cardiovascular care. 84% of surveyed KOLs said these technologies are likely or very likely to become part of routine lipid management.

Expected use cases include AI-supported risk stratification, automated identification of undertreated high-risk patients within EHR data, and clinical decision support for treatment intensification timing.

84%
Likely / Very likely to become part of routine lipid management

Emerging AI-supported lipid management workflow

The opportunity lies less in generic AI wellness tools and more in embedded clinical decision support for lipid risk and treatment management.

01
AI-supported risk stratification
02
Identification of undertreated high-risk patients
03
Lp(a) / ApoB patient identification
04
Cardiovascular risk trajectory modeling
05
Treatment intensification decision support
06
Embedded clinical decision support
Industry Perspective

Four Shifts Reshaping Lipid Disorder Management

The survey points to a field moving beyond statin dominance toward targeted therapies, personalized cardiovascular risk assessment, technology-enabled care and access solutions.

01

Statin-Centered Care → Expanded Non-Statin Therapy

Expanded non-statin and targeted lipid-lowering therapies, including oral PCSK9 inhibition, are identified as a leading recent advancement.

02

LDL-C Alone → Multidimensional Risk Assessment

Lp(a), ApoB, genetic testing and other biomarkers are becoming central to cardiovascular risk assessment.

03

Conventional Care → AI-Supported Management

Digital health and AI-supported tools are expected to support risk stratification, patient identification and treatment intensification decisions.

04

Therapeutic Innovation → Access & Implementation

Treatment cost, insurance restrictions and prior authorization requirements remain the leading barrier to broader implementation.

The Emerging Model

The Future Is Convergent

The future of lipid disorder management is unlikely to be defined by one category of innovation. Instead, the field is moving toward an interconnected model of therapy, biomarkers, digital support and access.

Non-Statin Therapies
+
Oral PCSK9 Inhibition
+
Lp(a) & ApoB
+
Personalized Risk
+
AI & Digital Health
+
Access & Reimbursement
Strategic Outcome More personalized, technology-supported lipid management
Strategic Implications

What This Means for Pharma, Biotech, MedTech & Healthcare SaaS

The survey shows a field where therapeutic innovation, biomarker development, digital monitoring and access strategy are increasingly interconnected.

“Pair therapeutic and diagnostic innovation with real solutions to cost and access barriers.”

Pharmaceutical & Biotech

Position around non-statin and targeted innovation

The KOL data supports continued investment in non-statin therapies, oral PCSK9 inhibition, combination therapy and long-acting lipid-lowering approaches.

Diagnostics & MedTech

Build around biomarker-driven risk assessment

Lp(a), ApoB and genetic testing are rated extremely important by 88% of KOLs, creating demand for approaches that connect diagnostics with treatment pathways.

Digital Health & AI

Prioritize embedded clinical decision support

The opportunity lies in tools that flag Lp(a)/ApoB-eligible patients, model cardiovascular risk trajectories and support intensification decisions at the point of care.

Market Access

Address cost and reimbursement friction

With 68% identifying treatment cost, insurance restrictions and prior authorization requirements as the greatest barrier, access strategy remains critical.

Conclusion

The future of lipid management is more targeted, personalized and connected.

This KOL perception survey makes clear that lipid disorder management is entering a new phase — one defined less by whether better tools exist and more by whether they can reach patients.

Oral PCSK9 inhibition and other non-statin therapies are reshaping what is clinically possible; Lp(a) and ApoB testing are redefining personalized cardiovascular risk assessment; and AI-supported tools are poised to move from novelty to clinical infrastructure.

At the same time, 68% identified treatment cost, insurance restrictions and prior authorization requirements as the greatest barrier to broader implementation.

For pharma, biotech, MedTech, and healthcare SaaS organizations, the strategic priority is unmistakable: pair therapeutic and diagnostic innovation with real solutions to cost and access barriers, because that is where the next decade of dyslipidemia care will be won or lost.

Non-Statin Therapies Oral PCSK9 Lp(a) + ApoB AI-Supported Care Better Access
Frequently Asked Questions

Lipid Disorder Management KOL Insights FAQs

Lipid disorder management refers to the clinical approach to diagnosing, monitoring, and treating abnormal cholesterol and lipoprotein levels — including LDL-C, Lp(a), and ApoB — to reduce cardiovascular disease risk.
Per KOL consensus, expanded non-statin therapies — particularly oral PCSK9 inhibitors — represent the most significant recent advancement, followed by combination therapy and long-acting, infrequently dosed agents.
Lp(a) and ApoB capture cardiovascular risk that LDL-C alone can miss, particularly in patients with genetically elevated Lp(a) or discordant lipid profiles, enabling more personalized lipid management.
Cost, insurance restrictions, and prior authorization requirements are the leading barrier, cited by over two-thirds of KOLs surveyed — ahead of adherence, specialist access, or biomarker testing limitations.
Yes. The majority of cardiovascular KOLs expect AI and digital health tools to support risk stratification, patient identification, and treatment intensification decisions in routine lipid management.
No — most KOLs view existing options as only partially adequate, citing residual cardiovascular risk and continued need for innovation, particularly for high-risk and statin-intolerant patients.
Highly optimistic — 94% of surveyed KOLs are optimistic or very optimistic about the trajectory of lipid disorder management over the next decade.
Strategic Intelligence

Turn Cardiovascular KOL Intelligence
Into Strategic Action

Understand how leading cardiovascular and lipidology experts view non-statin therapies, biomarkers, AI, treatment access and the future of lipid disorder management.

Explore KOL Intelligence
Download Full Report (PDF)
Thought Leadership

Trusted by Industry Leaders

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-Danaher
SPER-AandM
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken
HIPPA Compliant
GDPR Certified
ISO 27001
Peer Reviewed
Get Started Today

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.

Schedule Consultation Explore AI Platforms
No Credit Card Required
15-Minute Demo
Expert Guidance